A Rocky First Quarter For Big Pharma Stocks
Executive Summary
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
You may also be interested in...
AbbVie Presents Optimistic Take For 2020, Expects Quick Recovery For Botox Aesthetic
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
Amgen Optimistic About 2020 Despite COVID-19 Impacts
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.
Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term
The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.